News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celgene International Sárl (CELG) Two Studies Evaluating the Combination of REVLIMID® and rituximab in Non-Hodgkin’s Lymphomas Presented at International Conference on Malignant Lymphoma


6/20/2013 9:09:25 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that results from two studies evaluating the combination of REVLIMID® (lenalidomide) and rituximab in various non-Hodgkin’s lymphomas were presented at the 12th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES